Walleye Capital LLC Chinook Therapeutics, Inc. Transaction History

Walleye Capital LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$18.66 - $38.58 $6.23 Million - $12.9 Million	-334,088 Reduced 84.77%	60,012 $2.31 Million
Q1 2023 May 15, 2023	BUY	$21.53 - $26.8 $5.66 Million - $7.04 Million	262,725 Added 199.98%	394,100 $9.12 Million
Q4 2022 Feb 14, 2023	SELL	$18.63 - $27.35 $3.09 Million - $4.54 Million	-166,009 Reduced 55.82%	131,375 $3.44 Million
Q3 2022 Nov 14, 2022	BUY	$17.51 - $23.37 $365,013 - $487,171	20,846 Added 7.54%	297,384 $5.85 Million
Q2 2022 Aug 08, 2022	BUY	$12.59 - $18.8 $1.3 Million - $1.94 Million	103,035 Added 59.39%	276,538 $4.84 Million
Q1 2022 May 16, 2022	SELL	$12.02 - $16.69 $36,636 - $50,871	-3,048 Reduced 1.73%	173,503 $2.84 Million
Q4 2021 Mar 03, 2022	BUY	$10.69 - $16.83 $1.89 Million - $2.97 Million	176,551 New	176,551 $2.88 Million
Q3 2021 Nov 15, 2021	SELL	$11.5 - $14.86 $190,520 - $246,185	-16,567 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$13.6 - $18.98 $225,311 - $314,441	16,567 New	16,567 $234,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.